Skip to main content
Erschienen in: Die Kardiologie 4/2019

29.07.2019 | Arterielle Hypertonie | CME Zertifizierte Fortbildung

Arterielle Hypertonie bei Menschen mit Diabetes

verfasst von: Prof. Dr. Walter Zidek

Erschienen in: Die Kardiologie | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus und arterielle Hypertonie kommen häufig gemeinsam vor. Die zielorientierte Therapie des Bluthochdrucks verbessert die kardiovaskuläre Prognose bei Diabetes signifikant. Gleichzeitig ist die Hypertoniebehandlung bei Menschen mit im Vergleich zu solchen ohne Diabetes schwieriger. Insulinresistenz und Aktivierung des Renin-Angiotensin-Systems (RAS) sind wesentliche pathogenetische Faktoren. Die Zielblutdruckwerte wurden in den letzten Jahren unterschiedlich formuliert. Eine Blutdrucksenkung <130/80 mm Hg dürfte eine optimale kardiovaskuläre Protektion ermöglichen. Ein Blutdruck <120 mm Hg systolisch sollte vermieden werden. Zur Behandlung werden primär RAS-Blocker, Kalziumantagonisten und Diuretika verwendet. Betablocker sind primär nur bei zwingender kardialer Indikation sinnvoll. Bei diabetischer Nephropathie beginnt die Therapie mit einem RAS-Blocker. Die nächtliche Hypertonie bei autonomer Neuropathie erfordert besondere Aufmerksamkeit.
Literatur
2.
Zurück zum Zitat Hu G, Jousilahti P, Tuomilehto J (2007) Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 28:3059–3066CrossRefPubMed Hu G, Jousilahti P, Tuomilehto J (2007) Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 28:3059–3066CrossRefPubMed
3.
Zurück zum Zitat Reboldi G, Gentile G, Angeli F et al (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253–1269CrossRefPubMed Reboldi G, Gentile G, Angeli F et al (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253–1269CrossRefPubMed
4.
Zurück zum Zitat De Cosmo S, Viazzi F, Pacilli A et al (2015) Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant 30:1526–1533CrossRefPubMed De Cosmo S, Viazzi F, Pacilli A et al (2015) Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant 30:1526–1533CrossRefPubMed
5.
Zurück zum Zitat Group AS, Cushman WC, Evans GW et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRef Group AS, Cushman WC, Evans GW et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRef
6.
Zurück zum Zitat ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRef
7.
Zurück zum Zitat Group SR, Wright JT Jr., Williamson JD et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116CrossRef Group SR, Wright JT Jr., Williamson JD et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116CrossRef
8.
Zurück zum Zitat Buckley LF, Dixon DL, Wohlford GF et al (2017) Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care 40:1733–1738CrossRefPubMed Buckley LF, Dixon DL, Wohlford GF et al (2017) Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care 40:1733–1738CrossRefPubMed
9.
Zurück zum Zitat Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefPubMed
10.
Zurück zum Zitat Group AC, Patel A, Macmahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef Group AC, Patel A, Macmahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
11.
Zurück zum Zitat Jafar TH, Stark PC, Schmid CH et al (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139:244–252CrossRefPubMed Jafar TH, Stark PC, Schmid CH et al (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139:244–252CrossRefPubMed
12.
Zurück zum Zitat Grassi G, Mancia G, Nilsson PM (2016) Specific blood pressure targets for patients with diabetic nephropathy? Diabetes Care 39(Suppl 2):S228–S233CrossRefPubMed Grassi G, Mancia G, Nilsson PM (2016) Specific blood pressure targets for patients with diabetic nephropathy? Diabetes Care 39(Suppl 2):S228–S233CrossRefPubMed
13.
Zurück zum Zitat Patel A, Macmahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed Patel A, Macmahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRefPubMed
14.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36:1953–2041CrossRefPubMed Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36:1953–2041CrossRefPubMed
15.
Zurück zum Zitat Margolis KL, O’connor PJ, Morgan TM et al (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37:1721–1728CrossRefPubMedPubMedCentral Margolis KL, O’connor PJ, Morgan TM et al (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37:1721–1728CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Emdin CA, Rahimi K, Neal B et al (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed Emdin CA, Rahimi K, Neal B et al (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed
18.
Zurück zum Zitat Investigators O, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRef Investigators O, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRef
19.
Zurück zum Zitat Fernandez Juarez G, Luno J, Barrio V et al (2013) Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 61:211–218CrossRefPubMed Fernandez Juarez G, Luno J, Barrio V et al (2013) Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 61:211–218CrossRefPubMed
20.
Zurück zum Zitat Holtkamp FA, De Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287CrossRefPubMed Holtkamp FA, De Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287CrossRefPubMed
21.
Zurück zum Zitat Romano S, Idolazzi C, Fava C et al (2018) Prevalence and comorbidities of resistant hypertension: a collaborative population-based observational study. High Blood Press Cardiovasc Prev 25:295–301CrossRefPubMed Romano S, Idolazzi C, Fava C et al (2018) Prevalence and comorbidities of resistant hypertension: a collaborative population-based observational study. High Blood Press Cardiovasc Prev 25:295–301CrossRefPubMed
22.
Zurück zum Zitat Van Schoonhoven AV, Van Asselt ADI, Tomaszewski M et al (2018) Cost-utility of an objective biochemical measure to improve adherence to antihypertensive treatment. Hypertension 72:1117–1124CrossRefPubMed Van Schoonhoven AV, Van Asselt ADI, Tomaszewski M et al (2018) Cost-utility of an objective biochemical measure to improve adherence to antihypertensive treatment. Hypertension 72:1117–1124CrossRefPubMed
23.
Zurück zum Zitat Williams B, Macdonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068CrossRefPubMedPubMedCentral Williams B, Macdonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386:2059–2068CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Chen Y, Liu P, Chen X et al (2018) Effects of different doses of Irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci 355:418–424CrossRefPubMed Chen Y, Liu P, Chen X et al (2018) Effects of different doses of Irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci 355:418–424CrossRefPubMed
25.
Zurück zum Zitat Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation 137:323–334CrossRefPubMedPubMedCentral Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation 137:323–334CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed
27.
Zurück zum Zitat Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:2098–2107CrossRefPubMed Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:2098–2107CrossRefPubMed
28.
Zurück zum Zitat Tsimihodimos V, Filippatos TD, Elisaf MS (2018) SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr 12:1117–1123CrossRefPubMed Tsimihodimos V, Filippatos TD, Elisaf MS (2018) SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr 12:1117–1123CrossRefPubMed
29.
Zurück zum Zitat Mancia G, Cannon CP, Tikkanen I et al (2016) Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 68:1355–1364CrossRefPubMed Mancia G, Cannon CP, Tikkanen I et al (2016) Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 68:1355–1364CrossRefPubMed
30.
Zurück zum Zitat Mazidi M, Rezaie P, Gao HK et al (2017) Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6(6):e4007CrossRefPubMedPubMedCentral Mazidi M, Rezaie P, Gao HK et al (2017) Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6(6):e4007CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Jordan J, Shannon JR, Pohar B et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10:35–42PubMed Jordan J, Shannon JR, Pohar B et al (1999) Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 10:35–42PubMed
32.
Zurück zum Zitat Shibao C, Gamboa A, Abraham R et al (2006) Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47:522–526CrossRefPubMed Shibao C, Gamboa A, Abraham R et al (2006) Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47:522–526CrossRefPubMed
Metadaten
Titel
Arterielle Hypertonie bei Menschen mit Diabetes
verfasst von
Prof. Dr. Walter Zidek
Publikationsdatum
29.07.2019
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 4/2019
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-019-0342-1

Weitere Artikel der Ausgabe 4/2019

Die Kardiologie 4/2019 Zur Ausgabe